Clinical trials: Clinical Research
Gingivitis, Plaque, Dental
Gingivitis Reduction After Use of 0.45% Stannous Fluoride Toothpaste
The 6-month clinical study was designed to investigate clinical efficacy on plaque and gingivitis for the stannous fluoride containing toothpaste (SNAP) compared to Colgate Cavity Protection Toothpaste after 3 and 6 months of…
- Trial name
- NCT06300866
- Testing
- Test, Control
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Colgate Palmolive
Smoking Cessation
Pharmacokinetic Study of 4 mg Nicotine Lozenge.
This is a randomized, single center, open label, single dose, four way crossover study in fasted healthy male subjects to compare the pharmacokinetics of nicotine following administration of 3 prototype 4mg nicotine lozenge to an…
- Trial name
- NCT01669122
- Testing
- nicotine
- Where
- India
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis B
Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection.
The purpose of this study is to determine the safety and antiviral HBV activity of ACH-126,443 (beta-L-Fd4C) in the treatment of Subjects of Previous Achillion-Sponsored Phase 1 and 2 Studies in Chronic Hepatitis B Infection.
- Trial name
- NCT00037622
- Testing
- ACH-126, 443 (beta-L-Fd4C)
- Volunteers
- 100 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Healthy
Bioequivalence of a Single Subcutaneous Dose of BEPO and REPO in Healthy Male Subjects
To Compare Pharmacokinetic and Pharmacodynamic Profiles of BEPO-A and REPO-A in Healthy Male Subjects
- Trial name
- NCT02426151
- Testing
- BEPO-A, REPO-A
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Healthy Volunteers
Effect of Teduglutide on Gastric Emptying in Healthy Subjects
The primary objective of this study is to assess the effects of 10 consecutive, daily, subcutaneous doses of 4 mg of teduglutide as compared with placebo on gastric emptying as assessed by acetaminophen absorption kinetics in…
- Trial name
- NCT01209351
- Testing
- teduglutide
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Shire
Diabetes Mellitus Type 1
Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes
The primary objective of this study is to assess the speed of absorption and onset of action of BIOD-105 and BIOD-107 and compare them to Humalog®.
- Trial name
- NCT01334151
- Testing
- Insulin LISPRO, recombinant human insulin
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Biodel
Ovarian Cancer
Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy
The purpose of this study is to determine whether the investigational drug catumaxomab delivered in the planned treatment schedule is a safe and effective treatment for women with advanced ovarian cancer who experience a complete…
- Trial name
- NCT00377429
- Testing
- catumaxomab
- Where
- 12 sites in United States
- Volunteers
- 47 people
- Sponsor
- Neovii Biotech
Endovascular Procedures
Safety and Accuracy of the Saranas EBBMS for the Detection of Endovascular Procedure Related Bleeding Events
To evaluate the safety and accuracy of the Saranas EBBMS for the detection of access site related internal bleeding events during large-bore endovascular procedures.
- Trial name
- NCT03621202
- Testing
- Saranas Early Bird Bleed Monitoring System (EBBMS)
- Where
- 5 sites in United States
- Volunteers
- 66 people
- Sponsor
- Saranas, Inc.
Multiple Myeloma (MM)
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
The purpose of this study is to evaluate if the addition of SCTC21C to bortezomib, lenalidomide and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma not eligible for transplant will prolong progression-free…
- Trial name
- NCT07297329
- Testing
- SCTC21C, Bortezomib, Lenalidomide
- Where
- China
- Volunteers
- 292 people
- Sponsor
- Sinocelltech Ltd.
Chronic Hepatitis B
A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects With Chronic Hepatitis B Virus Infection
This is a randomized, blinded, placebo-controlled, dose-ranging Phase 1b study of the safety, PK, and antiviral activity of ABI-4334 in treatment-naïve or off-treatment chronic Hepatitis B virus (cHBV) subjects that are Hepatitis…
- Trial name
- NCT06384131
- Testing
- ABI-4334
- Where
- 2 sites in Moldova, New Zealand
- Volunteers
- 20 people
- Sponsor
- Assembly Biosciences
Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer
This is a multicenter, open-label, non-controlled, phase I study to investigate the tolerability and safety of ONO-4578 used in combination with standard-of-care letrozole and a CDK4/6 inhibitor (palbociclib or Abemaciclib) as…
- Conditions
- Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT06570031
- Testing
- ONO-4578, letrozole, Palbociclib
- Where
- 13 sites in Japan
- Volunteers
- 46 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Healthy
Bioavailability of Oral BIRB 796 BS Tablets With and Without Administration of Oral Pantoprazole in Healthy Male Volunteers
Study to assess the effect of gastric pH on the pharmacokinetics of BIRB 796 BS. Safety and tolerability were also assessed.
- Trial name
- NCT02209831
- Testing
- BIBR 796 BS, Pantoprazole
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Bioequivalence
A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers
Bioequivalence study between two inhaler products of fixed dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder
- Trial name
- BREATH-PK500 (NCT03751202)
- Testing
- Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg, ADVAIR DISKUS
- Where
- Greece
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Respirent Pharmaceuticals Co Ltd.
Bladder Cancer, Urothelial Carcinoma
A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
This global, randomized, controlled, open-label Phase 3 study was designed to assess the long-term efficacy and safety of UGN-102 (mitomycin) for intravesical solution with or without (±) transurethral resection of bladder tumors…
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
- Trial name
- ATLAS (NCT04688931)
- Testing
- UGN-102, TURBT
- Where
- 139 sites in United States, Bulgaria and 8 more
- Volunteers
- 282 people
- Sponsor
- UroGen Pharma Ltd.
Infection, Human Immunodeficiency Virus
A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy Subjects
The purpose of this study is to estimate the effect of high fat meal and increased gastric pH on BMS-663068 bioavailability
- Trial name
- NCT02666053
- Testing
- BMS-663068
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Eye Strain, Eye Strain of Both Eyes
Study of Non-inferiority Between Manzanilla Sophia® and Meticel Ofteno® 0.5% for Providing a Soothing Sensation to the Eyes.
This is a phase IV clinical study to demonstrate the non-inferiority of Manzanilla Sophia® compared to Meticel Ofteno® 0.5% in providing restful sensation to the eyes.
- Trial name
- NCT06373653
- Testing
- Manzanilla Sophia®, Meticel Ofteno®
- Volunteers
- healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Myelofibrosis, Primary Myelofibrosis
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
The purpose of the study is to compare the efficacy and safety of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis who have suboptimal response while receiving…
- Conditions
- Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
- Trial name
- NCT04551053
- Testing
- parsaclisib, ruxolitinib
- Where
- 177 sites in United States, Austria and 17 more
- Volunteers
- 177 people
- Sponsor
- Incyte Corporation
Healthy
First-in-Human Single and Multiple Dose of GLPG1837
The purpose of this First-in-Human study is to evaluate the safety and tolerability after single ascending oral doses of GLPG1837 given to healthy subjects, compared to placebo.
- Trial name
- NCT02325037
- Testing
- GLPG1837 single ascending doses, GLPG1837 multiple ascending doses
- Where
- Belgium
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
Severe Spasticity
Safety Study of 3 mg/mL Baclofen Injection (Intrathecal) Using A Programmable Pump
Safety study to assess the 3 mg/mL baclofen injection (intrathecal) using a programmable pump
- Trial name
- NCT01520545
- Testing
- Gablofen® 3 mg/mL (baclofen injection), SynchroMed® II Programmable Pump
- Where
- 13 sites in United States
- Volunteers
- 153 people
- Sponsor
- Piramal Critical Care, Ltd.
Aortic Valve Disease
KONECT RESILIA Aortic Valved Conduit (AVC) Real-world Study Assessing Safety and Performance
KONECTION is a prospective, observational, single-arm, multicenter study designed to collect real-world clinical outcomes in up to 250 participants who will receive the KONECT RESILIA aortic valved conduit, Model 11060A.
- Trial name
- KONECTION (NCT07619872)
- Testing
- Edwards KONECT RESILIA AVC
- Where
- 3 sites in Germany
- Volunteers
- 250 people
- Sponsor
- Edwards Lifesciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.